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Abstract
Cowden syndrome is a rare hereditary disease. Incidence of the disease is
conditioned by occurrence of mutations in the PTEN gene. The disease has
a frequency of 1/120,000 newborn and it predisposes to the occurrence of
hamartoma polyps in the gastrointestinal tract, skin tumours, as well as tumours
of the breast, ovary and thyroid. Here we describe the case of a Polish patient
diagnosed with Cowden syndrome with an identified mutation in the PTEN gene.
The disease course of the patient is described and discussed along with other
cases of carriers of substitution 68T>A in the PTEN gene.
K Ke ey y   w wo or rd ds s: : Cowden syndrome, PTEN gene, Polish population.
Introduction
Cowden syndrome (CS) is also known as multiple hamartoma syndrome.
Cowden syndrome was first described in 1963 by Lloyd and Dennis, who
named the disease after their patient Rachel Cowden. It is a rare inheritable
disease with autosomal dominant inheritance, characterised by skin
findings and hamartomas. The first pathognomonic symptoms of CS are
usually diagnosed in the second decade of life. Almost all patients develop
hamartomas, which have ectodermal, mesodermal and endodermal origin.
These multiple non-cancerous, tumour-like growths occur especially in
skin, mucosal membranes, breasts, brain, endometrium and thyroid. More
than  70%  of  patients  with  CS  have  hamartoma  polyps  in  the
gastrointestinal tract, mostly in the colorectum, but the polyps may also
exist in the stomach and duodenum. Typical dermatopathology detected
in  CS  comprises  mucocutaneous  lesions  such  as  trichilemmomas,
cobblestone-like papules, or acral or palmoplantar keratoses. Macrocephaly
has been reported in 80% of cases. Other symptoms of CS, such as mental
retardation and non-cancerous brain tumour called Lhermitte-Duclos
disease, are observed infrequently. Among patients with CS, increased risk
for many cancers is observed. The most common tumours are breast
cancer in women, and thyroid cancer in both men and women. Carcinoma
of thyroid and breast are present in approximately 60% and 20-36% of
patients, respectively. Apart from adenocarcinoma of the colon or another
part of the gastrointestinal tract, genitourinary cancer, lipomas, fibromas
and neuromas have also been observed. Cowden syndrome is caused by
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( (s se ex x, ,   a ag ge e) ) l le es si io on n
Patient 1* + Ca(46) –– – –
903I-2 (F)
Patient 2* + Ca(24) – Follicular ca (18) –– Liver
903II-1 (F) haemangioma 
Patient 3* + Ca(24) Simple  Follicular  Macrocephaly Hyperplasic Liver
Pid1 (F) hyperplasia ca (13) colon polyps haemangioma
(48) (43) (423)  (35)
Patient 4 + Papilloma  Polyp  Macrocephaly Hyperplasic –
1003 F (64) (57) (46) colon polyps 
(614)
T Ta ab bl le e   I I. .   Clinical features of CS patients with 68T>A 
The numbers in parentheses indicate the age of disease onset. Patients with * were described elsewhere by Lynch and Rustand (Lynch, Ostermeyer
et al. 1997; Rustad, Bjrrnslett et al. 2006). CNS – central nervous system
mutation in the PTEN gene (also known as MMAC1
[mutated in multiple advanced cancers] or TEP1 [TGF-
regulated and epithelial cell-enriched phosphatase])
[1,  2].  This  tumour  suppressor  gene,  encoding
phosphatase  with  protein  substrates,  lies  on
chromosome 10q23. PTEN protein controls other
molecules by removing phosphate groups. This
cytoplasmic protein is involved in many cellular
processes, and is active in various pathways, for
example it negatively controls phosphoinositide 
3-kinase signalling, plays a role in maintenance of
cellular structure, interactions with the extracellular
matrix, cell migration and invasion, and promotes
cell death [3]. 
Case report
The patient was a 63-year-old woman with
familial history of gastrointestinal cancers. Medical
examinations showed the major criteria of the CS
classification, i.e. macrocephaly, skin lesions, and
endometrial  and  breast  pathological  changes. 
A 7 cm fibroma mole was removed from the left
buttock at 53 years, and left and right mammary
gland papillomas were removed at 57 years. An
endometrial polyp was diagnosed at 47 years. The
clinical diagnostic studies also confirmed sebaceous
adenoma of head skin and colonoscopy revealed
four hyperplasic polyps. Polyps were located in the
descending colon and sigmoid colon. Moreover, 
a few diverticula were observed in the sigmoid
colon. The patient underwent cholecystectomy
performed at 48 years due to choledocholithiasis.
M Mo ol le ec cu ul la ar r   s st tu ud di ie es s
Since 2006, in the Institute of Human Genetics,
we  have  started  examining  hamartoma
syndromes including CS. DNA was extracted from
peripheral blood cells of the patient by the classical
phenol purification method [4]. Exon 1 of the PTEN
gene was amplified, using the following primers:
Prostate cancer 83   Liver cancer 82
Colorectal cancer 68 Venticular
cancer 74
F Fi ig gu ur re e   1 1. . Pedigree data
I : 1                   I : 2    
II : 4           II : 3           II : 1                  II : 2
III : 1          III : 2          III : 3         III : 4          III : 5
F Fi ig gu ur re e   2 2. . Sequencing of fragment of PTEN gene.
Arrow indicates the substitution 68T>AArch Med Sci 1, February / 2010 137
Polish Cowden syndrome patient with PTEN gene mutation
forward 5’-AGTCGCCTGTCACCATTT, and reverse
ACTACGGACATTTTCGCATC.  The  entire  coding
sequence of the PTEN gene was screened for
mutations using PCR-HD and PCR-SSCP analysis.
The PCR product encompassing exon 1 of the
PTEN gene, which showed an aberrant mobility
pattern in polyacrylamide gel electrophoresis as
compared  with  an  unaffected  control,  was
subjected  to  direct  cycle  sequencing.  The
sequence reaction product was analysed with an
MEGA BACE 500 DNA sequencer.
Discussion
As a result of this study, we detected a mutation
in the first exon of the PTEN gene. The detected
mutation was a transversion of T to A at nucleotide
68 and caused premature protein termination,
resulting in a change from TTA to TAA codon. The
substitution 68T>A is the first mutation detected
in a Polish patient with CS. The substitution 68T>A
is located in the N-terminal phosphatase domain.
Three  carriers  of  68T>A  have  been  described
previously (Table I) [5, 6]. We observed differences
in  relation  to  age  and  the  range  of  disease
symptoms in this group of patients (Table I).
All carriers of substitution 68T>A reveal skin
lesions and breast tumours. However, in our patient
(patient 4), the mammary gland papillomas were
removed and no adenomatous changes, which had
been described in all the other patients, were
observed (Table I). Remaining disease symptoms
were observed with considerable differentiation.
Macrocephaly, and gastrointestinal and endometrial
symptoms were only seen in patients 3 and 4. The
two remaining carriers of 68T>A demonstrated no
such lesions. In the presented group of 68T>A
carriers, both skin lesions and breast cancer were
observed, while in one patient (patient 3) the
course of CS was very severe [5, 6]. The significant
variation observed in the range and time of onset
of  disease  symptoms  in  carriers  of  the  same
mutation allowed the authors to conclude that the
course of the disease may be strongly affected by
genetic background.
The present study is the first report of molecular
confirmation of the clinical recognitions of CS with
mutation in the PTEN gene in Poland. The genetic
testing led us to identify individuals of high risk of
cancer occurrence, until clinical diagnostic studies
could be performed. Heterogeneity in the occurrence
of symptoms is observed but some cancers may
occur at a young age and the screening for cancer
may be performed in teenagers.
Acknowledgments
The  study  was  financed  by  the  Ministry of
Education and Science, Poland, grants number
2PO5E02630 and N N401 014435.
References
1. Nelen MR, van Staveren WC, Peeters EA, et al. Germline
mutations in the PTEN/MMAC1 gene in patients with
Cowden disease. Hum Mol Genet 1997; 6: 1383-7.
2. Nelen MR, Padberg GW, Peeters EA, et al. Localization of
the gene for Cowden disease to chromosome 10q22-23.
Nat Genet 1996; 13: 114-6.
3. Stiles B, Groszer M, Wang S, Jiao J, Wu H. PTENless means
more. Dev Biol 2004; 273: 175-84.
4. Slomski R, et al. Isolacja DNA. Przykłady analiz DNA, 2001;
3-7.
5. Rustad C, Bjřrnslett M, Heimdal KR, Mșhle L, Apold J,
Mřller P. Germline PTEN mutations are rare and highly
penetrant. Heredit Cancer Clin Pract 2006; 4: 177-85.
6. Lynch  ED,  Ostermeyer  EA,  Lee  MK,  et  al.  Inherited
mutations in PTEN that are associated with breast cancer,
cowden disease, and juvenile polyposis. Am J Hum Genet
1997; 61: 1254-60.